Project Description

FORCE Webinar:

Lineage Cell Therapeutics
Advanced Cell Therapy for Cancer, Vision Loss, and Spinal Cord Injuries


Date & Time:

September 23, 12:00 PM EDT
Webinar: Details provided upon RSVP approval

About the Event:

Lineage Cell Therapeutics (NYSE: LCTX) uses a proprietary cell-based therapy platform to either replace dysfunctional cells or cells that are absent due to degenerative disease or traumatic injury. They can also be used to help the body mount an effective immune response to cancer.

Currently, LCTX is clinical trials with three cell therapy programs:

OpRegen treats the leading cause of irreversible vision loss in the U.S., Dry Age-related Macular Degeneration (Dry AMD) and has been granted Fast Track designation from the FDA.

OPC1 treats acute spinal cord injuries (SCI), has received Regenerative Medicine Advanced Therapy (RMAT) designation and has also been granted Orphan Drug Designation by the FDA.

VAC2 is for patients with non-small cell lung cancer (NSCLC) and has the potential to stimulate a more robust immune response.

Join us September 23 at 12:00 EDT for a fireside chat between Lineage company leaders and one of their covering analysts, Jason McCarthy, Ph.D., Senior Managing Director covering biotechnology at Maxim Group about their promising platform and the opportunities that lie ahead for Lineage Cell Therapeutics.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.